Researchmoz added Most up-to-date research on "Broad Spectrum Of Treatment Available For Rhinoconjunctivitis In Global Market During The Period 2014 - 2020" to its huge collection of research reports.
Rhinoconjunctivitis
is a combination of rhinitis and conjunctivitis and is one of the most
common allergic reactions across the globe. It is an inflammatory
disorder which affects nasal and conjunctival mucosa and is induced as a
result of hypersensitive immune response. Rhinoconjunctivitis causes
symptoms of allergic rhinitis such as sneezing, watery mucus, itchy
nose, and nasal congestion, as well as conjunctivitis which include
burning sensation, tears and redness of eyes. These symptoms may also be
accompanied by systemic symptoms such as poor sleep, irritability and
fatigue. Allergic rhinoconjunctivitis is often mistaken with common cold
and a person may realize this only after carrying out considerable
allergy diagnostics. Various allergens are known to cause
rhinoconjunctivitis including pollen grains, dust and dust mites, animal
skin or dander, perfumes, smoke, hair and several others. Allergic
rhinitis is one of the most common allergic reactions in U.S. According
to National Institute for Health Research, more than 10 million
individuals in the U.K. suffer from allergic rhinitis. The institute
also explains that the over 90% of the individuals with allergic
rhinitis frequently suffer from ocular symptoms. An article published in
Journal of Allergy and Therapy mentions that allergic rhinitis is one
of the most common reasons for hospital visits due to allergies. Other
publications also report that majority of the patients with asthma also
suffer from rhinitis, and over 20% of patients with rhinoconjunctivitis
also have concomitant asthma.
A broad spectrum of
treatment is available for treatment of rhinoconjunctivitis. The
treatment for allergic conjunctivitis includes both topical as well as
systemic interventions such decongestants, mast-cell stabilizers,
antihistamines, nonsteroidal anti-inflammatory drugs, and intranasal
corticosteroids. In case of occasional symptoms, Claritin (loratadine),
Reactine (cetirizine), Aerius (desloratadine), Allegra (fexofenadine)
are prescribed. While if the symptoms are more frequent, intra-nasal
corticosteroids are prescribed which include Avamys, Flonase, Nasacort,
Nasonex, Omnaris, Rhinocort.
Article published in World
Allergy Organizations Journal in 2013 suggests that no accurate data is
available for studying the prevalence and its changing trends. This has
hampered the research and development activities. The study also found
that the prevalence of non food allergies is also increasing rapidly in
Asia. Allergic asthma is also a rising concern for many countries. More
than 5 million people in the U.K. suffer from asthma. A report published
by European Environment and Health Information System, considerable
increase in prevalence was observed for rhinoconjunctivitis in Poland,
Romania and the Russia Federation for rhinoconjunctivitis. This
increasing prevalence is a major factor driving the global
rhinoconjunctivitis market. Consistent research and development, and
growing awareness about allergies would also support the growth,
especially in developing countries. Prevalence of allergic rhinitis has
increased considerably in adults as well as children. Consumption of
food that has been preserved extensively in refrigerators,
industrialization and air pollution are also responsible for the
increased prevalence according to a study published in Allergy, Asthma
& Immunology Research Journal. Similar conditions prevail in India,
Korea, Singapore and other Asian countries.
Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=222448
Various pharmaceutical
companies and research institutes are conducting research for the
discovery for better treatment of the allergy. Merck Sharp & Dohme
Corp. is currently conducting phase III clinical trials for SCH 697243 a
biological drug, and another candidate MK-8237 is under phase I trials.
BioTech Tools S.A. is also developing gpASIT+TM as a potential
treatment for rhinoconjunctivitis. The study is currently under phase II
clinical trials. Such consistent research activities will add more
products in the market and expand its scope. Some of the key players in
the market include Johnson & Johnson Inc., Merck & Co., Inc.
GlaxoSmithKline, and Sanofi.
This research report
analyzes this market on the basis of its market segments, major
geographies, and current market trends. This report provides
comprehensive analysis of
Market growth drivers
- Factors limiting market growth
- Current market trends
- Market structure
- Market projections for upcoming years
This report is a complete
study of current trends in the market, industry growth drivers, and
restraints. It provides market projections for the coming years. It
includes analysis of recent developments in technology, Porter’s five
force model analysis and detailed profiles of top industry players. The
report also includes a review of micro and macro factors essential for
the existing market players and new entrants along with detailed value
chain analysis.
Reasons for Buying this Report
- This report provides pin-point analysis for changing competitive dynamics
- It provides a forward looking perspective on different factors driving or restraining market growth
- It provides a six-year forecast assessed on the basis of how the market is predicted to grow
- It helps in understanding the key product segments and their future
- It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
- It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments
- It provides distinctive graphics and exemplified SWOT analysis of major market segments
To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=222448
No comments:
Post a Comment